Versus Systems Inc. (VS) - Form 8-K Summary
Business Context and Reporting Period
Date of Report: October 7, 2024
Company: Versus Systems Inc.
Reporting Period: Current Report (Event Date: October 7, 2024)
Context: The Company entered into two material definitive agreements with ASPIS Cyber Technologies, Inc. ("ASPIS"), an affiliate of its largest shareholder, Cronus Equity Capital Group, LLC ("CECG"). These agreements are central to the Company's plan to regain compliance with Nasdaq's minimum shareholders' equity requirement of $2,500,000.
Key Financial Metrics and Transaction Details
Investment Amount: $2,500,000 total investment from ASPIS.
Payment Schedule:
- Initial Investment: $500,000 (to be funded on the "Initial Funding Date," which had not occurred as of the filing).
- Second Funding: $2,000,000 (due on or before November 15, 2024).
License Fee: $165,000 per month, commencing January 2025.
Equity Impact (Projected): Upon conversion and warrant exercise (assuming a $1.16 conversion rate), ASPIS would receive approximately 2,155,172 Common Shares and warrants to purchase 1,077,586 additional shares, resulting in ASPIS holding approximately 45.8% of outstanding shares.
Warrant Terms: Purchase price of $4.00 per share; exercisable for 5 years; 1 warrant per 2 shares.
Material Changes and Strategic Agreements
The filing details two primary agreements:
- Technology License and Software Development Agreement:
- ASPIS receives a perpetual, non-exclusive license to use Versus Technology (gamification, engagement, QR code) for its cybersecurity business.
- ASPIS will fund development of "Modified Technology" and pay the monthly license fee.
- ASPIS holds an exclusive license to use Modified Technology in the cybersecurity industry contingent on fee payment.
- Initial term of one year with renewal options.
- Business Funding Agreement:
- Provides the capital necessary to meet Nasdaq Listing Rule 5550(b)(1).
- Conversion of the note into Units (Common Share + Warrant) is contingent upon shareholder approval and the Company's redomiciling to Delaware, expected at the annual meeting in December 2024.
- Conversion rate is the greater of the 5-day VWAP or $1.16 per share.
Outlook, Risks, and Contingencies
Compliance Plan: The Investment Documents form the basis of the Company's plan submitted to Nasdaq to regain compliance with the $2.5 million shareholders' equity requirement. The Company expects to maintain this level until at least September 30, 2025.
Contingencies:
- Nasdaq Approval: If Nasdaq denies the Company's Plan, the $2,000,000 second funding is suspended until the deficiency is rectified.
- Shareholder Approval: Conversion of the note to equity requires shareholder approval and redomiciling to Delaware.
- Additional Funding: If Nasdaq requires more than $2.5 million, ASPIS has the exclusive right/obligation to provide the "Additional Amount."
- Uncertainty regarding Nasdaq's acceptance of the compliance plan.
- Risk of delisting if compliance is not achieved within required timelines.
- Potential material adverse effect on share liquidity and trading price if delisted.
- Uncertainty regarding long-term synergies with ASPIS.
Investor Verification Checklist
- Shareholder Approval: Verify if the Company successfully obtains shareholder approval for the equity issuance and redomiciling to Delaware at the December 2024 annual meeting.
- Nasdaq Status: Confirm whether Nasdaq has accepted the Company's Compliance Plan and if the $2.5 million equity threshold has been met.
- Funding Execution: Monitor the receipt of the initial $500,000 and the subsequent $2,000,000 by November 15, 2024.
- Dilution Impact: Assess the impact of ASPIS potentially holding ~45.8% of outstanding shares on existing minority shareholders.
- Delisting Risk: Review any subsequent communications from Nasdaq regarding the Company's listing status if the plan is delayed or denied.